ORCID as entered in ROS

Select Publications
2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27403
,2017, 'Socioeconomic and psychosocial factors are associated with suboptimal outcomes in HIV-infected adults: a case-control analysis', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27399
,2016, 'Concomitant medication use in ART-experienced Australian adults: data from the PAART study', in Antiviral Therapy, International Medical Press, New York City, USA, presented at The 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, New York City, USA, 12 September 2016 - 13 September 2016
,2013, 'Moderate neurocognitive decline can be detected over a four-month period using the HIV-dementia scale', in JOURNAL OF NEUROVIROLOGY, SPRINGER, DC, Washington, pp. S51 - S51, presented at 12th International Symposium on NeuroVirology, DC, Washington, 29 October 2013 - 02 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325777200107&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2024, 'An open-label safety and feasibility pilot trial of ketamine-assisted psychotherapy for methamphetamine use disorder', Canberra, Australia, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'The GHB cultures, experiences and practices quantitative study', Canberra, Australia, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'Exploring the perceived usefulness of integration support after naturalistic psychedelic experiences in people concerned about their substance use: a survey', Wesley Conference Centre, Sydney NSW, presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024
,2023, 'GHB Cultures, practices, and experiences: A qualitative study exploring diverse cultures, practices and experiences of GHB use among cisgender or transgender people who identify as heterosexual and live in Australia', Melbourne, Australia, presented at Harm Reduction International, Melbourne, Australia, 16 April 2023 - 20 April 2023, https://hr23.hri.global/programme/
,2023, 'Help wanted: Recruiting and leading nurses in the setup of Australia’s first supervised injectable opioid treatment clinic', Melbourne, Australia, presented at Harm Reduction International, Melbourne, Australia, 16 April 2023 - 19 April 2023, https://hr23.hri.global/programme/
,2022, 'The Safety and Feasibility of Lisdexamfetamine for the Treatment of Acute Methamphetamine Withdrawal: Preliminary Results of an Open Label Pilot Study', Minneapolis, USA, presented at The College on Problems of Drug Dependence 84th Annual Scientific Meeting, Minneapolis, USA, 11 June 2022 - 15 June 2022, https://d2p55c5k0gw6a2.cloudfront.net/wp-content/uploads/2022/07/2022-CPDD-Abstract-Book.pdf
,2022, 'Clinically significant cognitive decline is uncommon in virally suppressed HIV. However, there was a signal for abnormal aging and complex impact of psychosocial and socio-economic factors on longitudinal cognitive performance', Virtual, presented at Conference on Retroviruses and Opportunistic Infections, Virtual, 14 February 2022 - 16 February 2022
,2021, 'A clinical research network approach to a trial of lisdexamfetamine for the treatment of acute methamphetamine withdrawal', Virtual, Vol. 40, pp. S132 - S133, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,2021, 'Towards an Australian clinical research network for methamphetamine and emerging drugs - outcomes of the National Centre for Clinical Research on Emerging Drugs Methamphetamine and Emerging Drugs Clinical Research Network Working Group', Virtual, Vol. 40, pp. S133 - S134, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,2021, 'Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials', Virtual, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,2021, 'Starting treatment in public drug and alcohol services in New South Wales: What can electronic medical records tell us about amphetamine type stimulant use?', Virtual, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,2021, 'Neurocognitive changes in adults with methamphetamine dependence treated with lisdexamfetamine compared with those with additional positive screening for childhood ADHD', presented at International Medicine in Addiction Conference, 26 February 2021 - 28 February 2021
,2019, 'STI incidence and risk factors in HIV-infected adults on antiretrovrial therapy (ART) in the PAART study', Perth, Australia, presented at Joint Australasian Sexual Health and HIV&AIDS Conference, Perth, Australia, 16 September 2019 - 19 September 2019
,2019, 'Safety of oral lisdexamfetamine in adults with methamphetamine dependence: a dose-escalating phase-2 study', San Antonio, Texas, USA, presented at The College on Problems of Drug Dependence 81st Annual Scientific Meeting, San Antonio, Texas, USA, 15 June 2019 - 19 July 2019
,2019, 'Developing a national prompt response network for Australia', Amsterdam, The Netherlands, presented at The 11th International Conference on Nightlife, Substance Use and Related Health Issues, Amsterdam, The Netherlands, 15 May 2019 - 17 May 2019
,2019, 'Towards a prompt response network for Australia: coordinated and rapid communication of information about events of concerns related to emerging substances', Maastricht, The Netherlands, presented at Sixth International Conference on Novel Psychoactive Substances, Maastricht, The Netherlands, 08 April 2019 - 09 April 2019
,2018, 'Failure of antiretroviral therapy (ART) in adults in Australia is mainly due to ART toxicity (an updated report with predictors of ART failure)', Sydney, Australia, presented at The Australasian HIV&AIDS Conference, Sydney, Australia, 24 September 2018 - 26 September 2018
,2018, 'Failure of antiretroviral therapy (ART) in adults in Australia is mainly due to ART toxicity (updated report with predictors of ART failure)', Amsterdam, the Netherlands, presented at 22nd International AIDS Conference, Amsterdam, the Netherlands, 23 July 2018 - 27 July 2018
,2018, 'Hospitalisations over a year follow-up in a cohort of adults living with HIV with sustained viral suppression in Australia', Amsterdam, the Netherlands, presented at 22nd International AIDS Conference, Amsterdam, the Netherlands, 23 July 2018 - 27 July 2018
,2017, 'Socioeconomic and psychosocial factors are associated with suboptimal outcomes in HIV-infected adults: a case-control analysis', Canberra, Australia, presented at The Australasian HIV&AIDS Conference, Canberra, Australia, 06 November 2017 - 08 November 2017
,2017, 'Failure of antiretroviral therapy (ART) in Australian adults is mainly due to ART toxicity', Milan, Italy, presented at The 16th European AIDS Conference, Milan, Italy, 25 October 2017 - 27 October 2017
,2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', Milan, Italy, presented at The 16th European AIDS Conference, Milan, Italy, 25 October 2017 - 27 October 2017
,2017, 'Socioeconomic and psychosocial factors are associated with suboptimal outcomes in HIV-infected adults: a case-control analysis', Milan, Italy, presented at The 16th European AIDS Conference, Milan, Italy, 25 October 2017 - 27 October 2017
,2015, 'Maraviroc-enhanced CART improves cognition in virally suppressed HAND: a pilot study', Seattle, USA, presented at The 22nd Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, 23 February 2015 - 26 February 2015
,2014, 'Safety and tolerability of, and adherence to, co-formulated emtricitabine-rilpivirine-tenofovir used as HIV non-occupational post-exposure prophylaxis in men who have sex with men', Sydney, Australia, presented at The St Vincent’s and Mater Health Research Symposium, Sydney, Australia, 11 September 2014 - 11 September 2014
,2013, 'Predictors of adherence to antiretroviral therapy in HIV-infected adults (the PAART pilot study)', Darwin, Australia, presented at The Australasian HIV&AIDS Conference, Darwin, Australia, 21 October 2013 - 23 October 2013
,2013, 'Moderate neurocognitive decline can be detected over a four-month period using the HIV-dementia scale (HDS)', Atlanta, USA, presented at The 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, USA, 03 March 2013 - 06 March 2013
,2024, 'A heuristic for evaluating methamphetamine withdrawal treatment programs', presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'Exploring service experiences among gay and bisexual men seeking to reduce or abstain from chemsex', presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'Exploring the perceived usefulness of integration support after naturalistic psychedelic experiences in people concerned about their substance use: A survey', presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'GHB-related emergency department presentations, hospitalisations and police seizures in New South Wales', presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'Implementing a national Prompt Response Network to improve health-led decision making and processes for emerging drugs', presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'Psilocybin-assisted psychotherapy for methamphetamine use disorder: A novel safety and feasibility trial', presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2023, 'Innovations beyond BC: Lisdexamfetamine for the treatment of methamphetamine use disorder and withdrawal', presented at The 5th Annual BC Substance Use Conference, Vancouver, Canada, 20 April 2023 - 23 April 2023
,2023, 'Strength in solidarity: Bringing together diverse local stakeholders to disseminate public drug information (presented on behalf of the Prompt Response Network)', presented at Harm Reduction International, Melbourne, Australia, 16 April 2023 - 19 April 2023, https://hr23.hri.global/programme/
,2022, 'An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial', presented at Lisbon Addictions, Lisbon, Portugal, 23 November 2022 - 25 November 2022
,2022, 'Co-designing an Australian Prompt Response Network', presented at Lisbon Addictions, Lisbon Addictions, 23 November 2022 - 25 November 2022
,2022, 'Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine', presented at Lisbon Addictions, Lisbon, Portugal, 23 November 2022 - 25 November 2022
,2022, 'Safety and tolerability of lisdexamfetamine for methamphetamine dependence and withdrawal, early experience from Australia: The LiMA Trial and OLAM pilot', presented at Annual Meeting Conference of the Norwegian Association for Addiction Medicine, Bergen, Norway, 02 November 2022
,2022, 'Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot safety and feasibility trial', presented at The 2022 APSAD Scientific Alcohol and Drugs Conference, Darwin, Australia, 09 October 2022 - 12 October 2022, https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.13537
,2022, 'Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: A retrospective medical record review', presented at The 2022 APSAD Scientific Alcohol and Drugs Conference, Darwin, Australia, 09 October 2022 - 12 October 2022, https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.13537
,2022, 'Phenobarbital to manage severe gammahydroxybutyrate withdrawal: A case series', presented at The 2022 APSAD Scientific Alcohol and Drugs Conference, Darwin, Australia, 09 October 2022 - 12 October 2022, https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.13537
,2022, 'AOD telephone counselling toolkit', presented at Drug and Alcohol Nurses Australasia Conference 2022, Adelaide, 03 August 2022 - 05 August 2022
,2022, 'Methamphetamine treatment landscape', presented at Drug and Alcohol Nurses Australasia Conference 2022, Adelaide, 03 August 2022 - 05 August 2022
,2022, 'OUTCOMES AND MEASURES USED IN RANDOMISED CONTROLLED TRIALS EXAMINING PHARMACOTHERAPIES FOR THE TREATMENT OF METHAMPHETAMINE WITHDRAWAL: RESULTS OF A SYSTEMATIC REVIEW', presented at The College on Problems of Drug Dependence 84th Annual Scientific Meeting, Minneapolis, USA, 11 June 2022 - 15 July 2022, https://d2p55c5k0gw6a2.cloudfront.net/wp-content/uploads/2022/07/2022-CPDD-Abstract-Book.pdf
,2022, 'Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials', presented at RANZCP 2022 Congress, Sydney, 15 May 2022 - 19 May 2022, http://dx.doi.org/10.1177/00048674221088686
,